Blanché H, Hager J, Sun F, Dausset J, Cohen D, Froguel P, Cohen N
Centre d'Etude du Polymorphisme Humain Fondation Jean Dausset-CEPH, Paris, France.
Biotechniques. 1994 May;16(5):866-8, 870, 873-6.
DNA mutations were previously identified in the glucokinase gene in 56% of French families affected with maturity onset diabetes of the young (MODY), an early onset autosomal dominant form of non-insulin-dependent diabetes mellitus (NIDDM). Mutations were found on almost all exons using the common radioactive single-strand conformation polymorphism (SSCP) technique. In this paper, we describe a non-isotopic SSCP method using the Pharmacia Biotech PhastSystem for the routine screening of new mutations in diabetic patients or in offsprings of diabetic patients. The use of the PhastSystem allowed us to easily and reproducibly optimize the electrophoretic conditions for each exon. We demonstrate the efficiency of this technique by identifying 8 mutations, 7 of which have never previously been detected, in patients referred to us for diagnostic purposes. It appears to be a sensible, easy and reliable method to improve the routine diagnosis of MODY in diabetic subjects or relatives and should be applicable to other genetic diseases.
先前在56%的法国青年发病的成年型糖尿病(MODY)家系中发现了葡萄糖激酶基因中的DNA突变,MODY是一种非胰岛素依赖型糖尿病(NIDDM)的早发性常染色体显性形式。使用常见的放射性单链构象多态性(SSCP)技术,在几乎所有外显子上都发现了突变。在本文中,我们描述了一种使用Pharmacia Biotech PhastSystem的非同位素SSCP方法,用于对糖尿病患者或糖尿病患者后代中的新突变进行常规筛查。使用PhastSystem使我们能够轻松且可重复地为每个外显子优化电泳条件。通过在转诊给我们进行诊断的患者中鉴定出8个突变,其中7个以前从未被检测到,我们证明了该技术的有效性。它似乎是一种合理、简便且可靠的方法,可改善糖尿病患者或亲属中MODY的常规诊断,并且应该适用于其他遗传疾病。